Table 3.
Impact of KIR on clinical outcomes in receptor ligand model.
| References | N | Disease | Donor | Graft manipulation | Clinical outcomes |
|---|---|---|---|---|---|
| Leung et al. (39) | 36 | Mixed | HRD | TCD* | Receptor ligand mismatch: lower relapse |
| Cook et al. (56) | 220 | Mixed | MSD | / | HLA-C2C2 patients vs. HLA-C1/x patients: lower OS (myeloid cohort) |
| Verheyden et al. (57) | 65 | Mixed | MSD | TCD*, TCR | HLA-C1C2 patients vs. HLA-C1C1 or C2C2 patients: lower aGVHD |
| Hsu et al. (58) | 1770 | Mixed | URD | TCR | Missing ligand for donor iKIR: lower relapse (HLA mismatched transplants) |
| Clausen et al. (59) | 43 | Mixed | MSD | TCR | Ligand missing to KIR3DL2 plus one other iKIR vs. others: lower relapse and higher OS |
| Ludajic et al. (60) | 124 | Mixed | URD | TCD#, TCR | Missing ligand for donor KIR2DL1: higher aGVHD2−4; |
| Linn et al. (61) | 151 | Mixed | MSD | TCR | Missing ligand for donor iKIR: no impact on OS and RFS |
| Wu et al. (62) | 48 | Mixed | URD | TCD# | HLA group C1 vs. C2: higher CMV reactivation rate |
| Gagne et al. (63) | 264 | Mixed | URD | TCR | Missing HLA-C1 ligand: lower OS (myeloid cohort) |
| Clausen et al. (64) | 100 | Mixed | MSD | TCR | HLA-C1C2 patients vs. HLA-C1C1 or C2C2 patients: lower relapse and aGVHD2−4, higher RFS |
| Björklund et al. (65) | 105 | AML, MDS | MSD | TCD#, TCR | Receptor ligand mismatch: no significant impact on OS, relapse and GVHD |
| Wu et al. (66) | 116 | Mixed | URD | TCD#, TCR | Missing ligand for donor iKIR: lower relapse, higher OS and DFS (myeloid cohort); |
| Zhou et al. (67) | 219 | Mixed | MSD | / | HLA-C1C1 patients vs. HLA-C2/x patients: lower aGVHD2−4 |
| Sobecks et al. (68) | 909 | AML, MDS | URD | TCD#, TCR | Missing ligand for donor iKIR: higher aGVHD3−4 and TRM (AML); Missing HLA-C2 for donor KIR2DL1: higher aGVHD2/3−4 (AML) |
| Park et al. (69) | 59 | Mixed | MSD, URD | TCD#, TCR | Receptor ligand mismatch: higher OS, DFS and lower relapse |
| Cardozo et al. (70) | 50 | Mixed | MSD | TCR | Patients with all ligands present vs. missing ligand for donor iKIR: higher aGVHD; Missing ligand for donor iKIR: higher OS (myeloid cohort) |
| Faridi et al. (71) | 281 | Mixed | MSD, URD | TCD# | Missing ligand for donor iKIR: lower relapse and better RFS (URD) |
| Neuchel et al. (72) | 1446 | Mixed | URD | TCR | HLA-C2C2 vs. HLA-C1/x patients: lower OS, DFS, higher relapse (myeloid cohort) |
| Arima et al. (73) | 10638 | Mixed | MSD, URD | TCD*, TCD# TCR |
HLA-C1C1 patients vs. HLA-C1C2 patients: lower relapse and higher RFS (AML and CML); HLA-C1C1 patients vs. HLA-C1C2 patients: higher relapse (ALL) |
| Gaafar et al. (74) | 87 | Mixed | MSD | TCR | KIR2DL1: HLA-C2 match: higher aGVHD2−4 (AML) |
| Arima et al. (75) | 2884 | ALL | MSD, URD | TCD, TCR | HLA-C1C1 patients vs. HLA-C1C2 patients: higher relapse |
| Chen et al. (76) | 84 | Mixed | HRD | TCD# | Missing HLA-C2 ligand for donor KIR2DL1: higher OS and lower RRM (myeloid cohort); Missing HLA-C for donor iKIR: lower aGVHD2−4 (lymphoid cohort); |
| Zhao et al. (77) | 97 | CML | HRD | TCD# | Receptor ligand match: lower relapse |
| Zhao et al. (78) | 188 | Mixed | HRD | TCD# | Receptor ligand match: lower relapse and higher LFS |
| Solomon et al. (79) | 208 | Mixed | HRD | TCD# | Receptor ligand mismatch: higher OS and DFS, lower relapse |
| Willem et al. (80) | 51 | Mixed | HRD | TCD# | KIR2DL/HLA mismatch: higher GVHD and lower relapse |
AL, acute leukemia; MDS, myelodysplastic syndromes; iKIR, inhibitory KIR; LFS, leukemia-free survival.